Jeffrey P. Callen
Abstract
Three tumor necrosis factor (TNF) antagonists are approved for the treatment of psoriasis — etanercept, adalimumab, and infliximab, all of which have
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Three tumor necrosis factor (TNF) antagonists are approved for the treatment of psoriasis — etanercept, adalimumab, and infliximab, all of which have
Key concepts: Medicine, Disease, Tumor necrosis factor alpha, Internal medicine, Pharmacology